Medical Oncology

, 31:864 | Cite as

ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24 phenotype

  • Ying Zhong
  • Songjie Shen
  • Yidong Zhou
  • Feng Mao
  • Jinghong Guan
  • Yan Lin
  • Yali Xu
  • Qiang Sun
Original Paper

Abstract

Breast cancer stem cells are thought to be associated with metastasis and poor prognosis, but their clinical importance remains poorly understood. The aim of this study was to investigate whether certain phenotypes of breast cancer stem cells were clinically important factors regarding metastasis. Patients with primary breast cancer (n = 121) were included in this study. Breast cancer stem cells were identified by immunohistochemical staining of CD44, CD24, and aldehyde dehydrogenase 1 (ALDH1) in tumor tissues from primary and recurrent or metastatic lesions. CD44+/CD24 cells and ALDH1+ cells were considered breast cancer stem cells. Sixty-five patients had metastatic or recurrent tumors. ALDH1+ tumors were significantly associated with a high rate of metastasis or recurrence (63.1 %; P = 0.026). Although there was no significant association between the proportion of CD44+/CD24 tumor cells and metastasis rates, a high proportion of CD44+/CD24 tumor cells was a risk factor for metastasis or recurrence (P = 0.035). Changes in the proportion of CD44+/CD24 or ALDH1+ tumor cells between primary lesions and recurrent lesions were studied in 27 patients. The proportion of ALDH1+ tumor cells increased significantly (P = 0.019) after recurrence, but the proportion of CD44+/CD24 tumor cells did not. Our findings suggest that ALDH1+ and CD44+/CD24 breast cancer stem cells play significant roles in metastasis. The rate of ALDH1+ cells appears to be a better predictive marker of breast cancer metastasis than the CD44+/CD24 phenotype.

Keywords

Breast cancer Cancer stem cell ALDH1 CD44+/CD24 Recurrence Metastasis 

Notes

Conflict of interest

All authors declare no conflict.

References

  1. 1.
    Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367(6464):645–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100(7):3983–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell. 2005;121(6):823–35.PubMedCrossRefGoogle Scholar
  4. 4.
    O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445(7123):106–10.PubMedCrossRefGoogle Scholar
  5. 5.
    Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396–401.PubMedCrossRefGoogle Scholar
  6. 6.
    Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44+/CD24−/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res. 2005;11(3):1154–9.PubMedGoogle Scholar
  7. 7.
    Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med. 2007;356(3):217–26.PubMedCrossRefGoogle Scholar
  8. 8.
    Grantzdorffer I, Yumlu S, Gioeva Z, von Wasielewski R, Ebert MP, Rocken C. Comparison of different tissue sampling methods for protein extraction from formalin-fixed and paraffin-embedded tissue specimens. Exp Mol Pathol. 2010;88(1):190–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Sprung RW Jr, Brock JW, Tanksley JP, Li M, Washington MK, Slebos RJ, et al. Equivalence of protein inventories obtained from formalin-fixed paraffin-embedded and frozen tissue in multidimensional liquid chromatography–tandem mass spectrometry shotgun proteomic analysis. Mol Cell Proteomics. 2009;8(8):1988–98.PubMedCrossRefGoogle Scholar
  10. 10.
    Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol. 2008;26(7):1059–65.PubMedCrossRefGoogle Scholar
  11. 11.
    Mylona E, Giannopoulou I, Fasomytakis E, Nomikos A, Magkou C, Bakarakos P, et al. The clinicopathologic and prognostic significance of CD44+/CD24(−/low) and CD44−/CD24+ tumor cells in invasive breast carcinomas. Hum Pathol. 2008;39(7):1096–102.PubMedCrossRefGoogle Scholar
  12. 12.
    Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA, et al. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med. 2009;13(8B):2236–52.PubMedCrossRefGoogle Scholar
  13. 13.
    Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555–67.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Resetkova E, Reis-Filho JS, Jain RK, Mehta R, Thorat MA, Nakshatri H, et al. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat. 2010;123(1):97–108.PubMedCrossRefGoogle Scholar
  15. 15.
    Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, et al. CD44+/CD24− breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006;8(5):R59.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Sun S, Wang Z. ALDH high adenoid cystic carcinoma cells display cancer stem cell properties and are responsible for mediating metastasis. Biochem Biophys Res Commun. 2010;396(4):843–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Wakamatsu Y, Sakamoto N, Oo HZ, Naito Y, Uraoka N, Anami K, et al. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathol Int. 2012;62(2):112–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Wang Y, Zhe H, Gao P, Zhang N, Li G, Qin J. Cancer stem cell marker ALDH1 expression is associated with lymph node metastasis and poor survival in esophageal squamous cell carcinoma: a study from high incidence area of northern China. Dis Esophagus. 2012;25(6):560–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28(10):1684–91.PubMedCrossRefGoogle Scholar
  20. 20.
    Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429–34.PubMedCrossRefGoogle Scholar
  21. 21.
    Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012;118(22):5463–72.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Ying Zhong
    • 1
  • Songjie Shen
    • 1
  • Yidong Zhou
    • 1
  • Feng Mao
    • 1
  • Jinghong Guan
    • 1
  • Yan Lin
    • 1
  • Yali Xu
    • 1
  • Qiang Sun
    • 1
  1. 1.Department of Breast DiseasePeking Union Medical College HospitalBeijingChina

Personalised recommendations